Abstract
Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Current Pharmaceutical Design
Title:Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Volume: 24 Issue: 1
Author(s): Adriana Trompetero, Aldemar Gordillo, Mora Carolina del Pilar, Velasquillo María Cristina and Rosa Helena Bustos Cruz*
Affiliation:
- Universidad de la Sabana, Faculty of Medicine, Therapeutic Evidence Group, Chía,Colombia
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Abstract: Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Export Options
About this article
Cite this article as:
Trompetero Adriana , Gordillo Aldemar, del Pilar Carolina Mora , Cristina María Velasquillo and Bustos Cruz Helena Rosa*, Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach, Current Pharmaceutical Design 2018; 24 (1) . https://dx.doi.org/10.2174/1381612823666170828133059
DOI https://dx.doi.org/10.2174/1381612823666170828133059 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research SS31, a Small Molecule Antioxidant Peptide, Attenuates β-Amyloid Elevation, Mitochondrial/Synaptic Deterioration and Cognitive Deficit in SAMP8 Mice
Current Alzheimer Research Conserved Domains, Residues, WebLogo and Active Sites of Caspase- Cascades Related to Apoptotic Signaling Pathway
Current Bioinformatics Editorial [ New Advances in Alzheimers Disease: From Biology to Therapy Guest Editor: Giuseppina Tesco ]
Current Genomics Estrogen Receptors: Mechanism of Action and Relevance to Schizophrenia
Current Psychiatry Reviews Mitigating Alzheimer’s Disease with Natural Polyphenols: A Review
Current Alzheimer Research Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry DNA Double Strand Breaks: A Common Theme in Neurodegenerative Diseases
Current Alzheimer Research Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins
Current Drug Discovery Technologies Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The “LEARn” Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD
Current Alzheimer Research A Novel Role of the STAT3 Pathway in Brain Inflammation-induced Human Neural Progenitor Cell Differentiation
Current Molecular Medicine Prion Protein Functions and Dysfunction in Prion Diseases
Current Medicinal Chemistry A Hypothesis for Regenerative Therapy for Neuronal Disease: Stem Cells within Artificial Niche
Current Signal Transduction Therapy